INFLUENCE OF NEOADJUVANT POLYCHEMOTHERAPY ON NATURAL-KILLER-CELL ACTIVITY IN PATIENTS WITH LOCALLY ADVANCED CERVICAL SQUAMOUS CARCINOMA

被引:16
|
作者
GARZETTI, GG [1 ]
CIAVATTINI, A [1 ]
PROVINCIALI, M [1 ]
VALENSISE, H [1 ]
ROMANINI, C [1 ]
FABRIS, N [1 ]
机构
[1] ITALIAN NATL RES CTR AGING, CTR IMMUNOL, DEPT RES, ANCONA, ITALY
关键词
D O I
10.1006/gyno.1994.1008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Peripheral blood natural killer (NK) cell activity against K562 tumor line was monitored in 16 patients with locally advanced squamous cervical carcinoma (II and Ill FIGO stages) during neoadjuvant polychemotherapy (cisplatin at 80 mg/m2 and blemycin at 30 mg/m2). There was a significant progressive decrease in NK activity during the three cycles of antiblastic treatment (P = 0.008) without significant depletion of NK cell (CD56 and CD16 monoclonal antibody positive cell percentage and absolute number). A significant relationship was shown between basal NK activity levels and response to polychemotherapy; in fact, nonresponder patients had a significantly lower mean value of NK activity before polychemotherapy than responders (P = 0.044). In conclusion, NK activity declines as a result of antiblastic therapy; although polychemotherapy reduces tumor spread, its antineoplastic action may be affected by this decreased immune reactivity. (C) 1994 Academic Press, Inc.
引用
收藏
页码:39 / 43
页数:5
相关论文
共 50 条
  • [41] SUPPRESSION OF NATURAL-KILLER-CELL ACTIVITY BY SERA FROM PATIENTS WITH ENDOMETRIOSIS
    KANZAKI, H
    WANG, HS
    KARIYA, M
    MORI, T
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1992, 167 (01) : 257 - 261
  • [42] DIMINISHED NATURAL-KILLER-CELL ACTIVITY OF INTERSTITIAL PULMONARY CELL-POPULATIONS FROM PATIENTS WITH CARCINOMA OF THE LUNG
    DESHAZO, RD
    MOULDER, PV
    BOZELKA, B
    CHAPMAN, Y
    CHEST, 1987, 91 (01) : 26 - 28
  • [43] Genomic characteristics in neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma
    He, Wenwu
    Leng, Xuefeng
    Wang, Kangning
    Mao, Tiaoqin
    Peng, Lin
    Fang, Qiang
    Xiao, Wenguang
    Han, Yongtao
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2020, 11 (06) : 1105 - 1112
  • [44] Neoadjuvant versus definitive chemoradiation for locally advanced esophageal squamous cell carcinoma
    Post, Carl M.
    Haefner, Matthias F.
    Lin, Chi
    Simone, Charles B., II
    Verma, Vivek
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S625 - S628
  • [45] INFLUENCE OF IMMUNOSUPPRESSION ON THE NATURAL-KILLER-CELL ACTIVITY OF RENAL-TRANSPLANT RECIPIENTS
    PARK, K
    KIM, YS
    KIM, SI
    KIDNEY INTERNATIONAL, 1991, 39 (01) : 212 - 212
  • [46] ANALYSIS OF NATURAL-KILLER ACTIVITY AND NATURAL-KILLER-CELL SUBSETS IN PATIENTS WITH BLADDER-CANCER
    MORITA, T
    TOKUE, A
    MINATO, N
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1990, 32 (03) : 191 - 194
  • [47] Neoadjuvant chemoradiotherapy followed by surgery in locally advanced squamous cell carcinoma of the vulva
    Gaudineau, A.
    Weitbruch, D.
    Quetin, P.
    Heymann, S.
    Petit, T.
    Volkmar, P.
    Bodin, F.
    Velten, M.
    Rodier, J. F.
    ONCOLOGY LETTERS, 2012, 4 (04) : 719 - 722
  • [48] NATURAL-KILLER-CELL ACTIVITY IN PATIENTS WITH HEPATOCELLULAR-CARCINOMA RELATIVE TO EARLY DEVELOPMENT AND TUMOR INVASION
    CHUANG, WL
    LIU, HW
    CHANG, WY
    CANCER, 1990, 65 (04) : 926 - 930
  • [49] Radiotherapy for patients with locally advanced esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy combined with chemotherapy
    Kong, Yue
    Su, Miaoyi
    Fang, Jun
    Chen, Mengyuan
    Zheng, Chao
    Jiang, Youhua
    Tao, Kaiyi
    Wang, Changchun
    Qiu, Guoqin
    Ji, Yongling
    Wang, Yuezhen
    Yang, Yang
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [50] The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
    Lv, Huilai
    Huang, Chao
    Li, Jiachen
    Zhang, Fan
    Gai, Chunyue
    Liu, Zhao
    Xu, Shi
    Wang, Mingbo
    Li, Zhenhua
    Tian, Ziqiang
    FRONTIERS IN IMMUNOLOGY, 2023, 13